HS-10522
/ Jiangsu Hansoh Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 28, 2026
A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension
(clinicaltrials.gov)
- P1 | N=88 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
New P1 trial • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1